Unknown

Dataset Information

0

OX40 is a potent immune-stimulating target in late-stage cancer patients.


ABSTRACT: OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function, and survival of T cells. Preclinical studies have shown that OX40 agonists increase antitumor immunity and improve tumor-free survival. In this study, we performed a phase I clinical trial using a mouse monoclonal antibody (mAb) that agonizes human OX40 signaling in patients with advanced cancer. Patients treated with one course of the anti-OX40 mAb showed an acceptable toxicity profile and regression of at least one metastatic lesion in 12 of 30 patients. Mechanistically, this treatment increased T and B cell responses to reporter antigen immunizations, led to preferential upregulation of OX40 on CD4(+) FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, and increased the antitumor reactivity of T and B cells in patients with melanoma. Our findings clinically validate OX40 as a potent immune-stimulating target for treatment in patients with cancer, providing a generalizable tool to favorably influence the antitumor properties of circulating T cells, B cells, and intratumoral regulatory T cells.

SUBMITTER: Curti BD 

PROVIDER: S-EPMC3922072 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function, and survival of T cells. Preclinical studies have shown that OX40 agonists increase antitumor immunity and improve tumor-free survival. In this study, we performed a phase I clinical tr  ...[more]

Similar Datasets

| S-EPMC6735535 | biostudies-literature
| S-EPMC8493970 | biostudies-literature
| S-EPMC5932227 | biostudies-literature
| S-EPMC11300540 | biostudies-literature
| S-EPMC8248740 | biostudies-literature
| S-EPMC4706056 | biostudies-literature
| S-EPMC7124947 | biostudies-literature
| S-EPMC9324127 | biostudies-literature
| S-EPMC8652148 | biostudies-literature
| S-EPMC2851732 | biostudies-literature